Recent Advances in Multiple Myeloma: Applying Real-World Evidence to Clinical Practice - Episode 10

Is There a Role for MRD-Response Adapted Therapy in Transplant-Eligible NDMM?

,

Dr Ajay Nooka describes key data from the uniquely-designed MASTER trial investigating daratumumab in combination with carfilzomib, lenalidomide and dexamethasone (Dara-KRd) versus KRd in transplant-eligible newly diagnosed multiple myeloma.